This sponsored study from multiple sites in North America is the first “real world” prospective inquiry into reasons underpinning the initiation and selection of agents between classes, as well as causes for switching or discontinuing therapy. The study is completely non-interventional in that neither the prescriber or patient is incentivized to choose between agents or start or stop any particular therapy. Over 1500 patients have been entered into the trial with preliminary demographic data having been presented at the International Continence Society meeting in 2017 in Florence, Italy4. Data continues to accrue which should provide some insights into OAB pharmacotherapy patterns of initiation, persistence, and discontinuation.
- Benner, J.S., Nichol, M.B., Rovner, E.S., et al: Patient-reported reasons for discontinuing overactive bladder medication. BJU Int.105(9):1276-82, 2010
- Yeaw, J. et al. J. Managed Care Pharm. 15:728-740, 2009
- Choo, M-S, et al: Changes in overactive bladder symptoms after discontinuation of successful 3- month treatment with an antimuscarinic agent: a prospective trial. J. Urol. 174: 201–204, 2005
- Rovner, E., Nair, K., Carlson, K., Oakkar, E., Park, J.< Velentgas, P., Kristy, R., Gooch, K., Schermer, C.: Baseline characteristics of patients initiating mirabegron or antimuscarinic treatment for overactive bladder: results from the PERSPECTIVE registry. ICS Meeting, Florence Italy, Sept. 2017
Read the Abstract